258 related articles for article (PubMed ID: 29383410)
1. [Pharmacogenetics in psychiatry: state of the art].
Müller DJ; Brandl EJ; Degenhardt F; Domschke K; Grabe H; Gruber O; Hebebrand J; Maier W; Menke A; Riemenschneider M; Rietschel M; Rujescu D; Schulze TG; Tebartz van Elst L; Tüscher O; Deckert J;
Nervenarzt; 2018 Mar; 89(3):290-299. PubMed ID: 29383410
[TBL] [Abstract][Full Text] [Related]
2. Genetic testing for CYP2D6 and CYP2C19 suggests improved outcome for antidepressant and antipsychotic medication.
Walden LM; Brandl EJ; Tiwari AK; Cheema S; Freeman N; Braganza N; Kennedy JL; Müller DJ
Psychiatry Res; 2019 Sep; 279():111-115. PubMed ID: 29699889
[TBL] [Abstract][Full Text] [Related]
3. Drugs and depression.
Harris B
Am J Nurs; 1986 Mar; 86(3):292-3. PubMed ID: 2869688
[No Abstract] [Full Text] [Related]
4. Pharmacogenetics and psychoactive drug therapy: ready for the patient?
Steimer W
Ther Drug Monit; 2010 Aug; 32(4):381-6. PubMed ID: 20526233
[TBL] [Abstract][Full Text] [Related]
5. High levels of several antipsychotics and antidepressants due to a pharmacogenetic cause: a case report.
Mian P; Somers M; Berg MT; Cahn W; Wilting I; Schaik RV
Pharmacogenomics; 2019 Jun; 20(8):567-570. PubMed ID: 31190622
[TBL] [Abstract][Full Text] [Related]
6. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants.
Sjöqvist F; Eliasson E
Clin Pharmacol Ther; 2007 Jun; 81(6):899-902. PubMed ID: 17392719
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics to prevent maniac affective switching with treatment for bipolar disorder: CYP2D6.
Sánchez-Martín A; Sánchez-Iglesias S; García-Berrocal B; Lorenzo C; Gaedigk A; Isidoro-García M
Pharmacogenomics; 2016 Aug; 17(12):1291-3. PubMed ID: 27469479
[No Abstract] [Full Text] [Related]
8. Pharmacogenetics of psychotropic drug response.
Malhotra AK; Murphy GM; Kennedy JL
Am J Psychiatry; 2004 May; 161(5):780-96. PubMed ID: 15121641
[TBL] [Abstract][Full Text] [Related]
9. The future of psychiatric pharmacogenomics.
Lohoff FW
Pharmacogenomics; 2011 Jul; 12(7):927-9. PubMed ID: 21787185
[No Abstract] [Full Text] [Related]
10. Is there a role for antidepressant and antipsychotic pharmacogenetics in clinical practice in 2014?
Mulsant BH
Can J Psychiatry; 2014 Feb; 59(2):59-61. PubMed ID: 24881124
[No Abstract] [Full Text] [Related]
11. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
12. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.
Hicks JK; Swen JJ; Thorn CF; Sangkuhl K; Kharasch ED; Ellingrod VL; Skaar TC; Müller DJ; Gaedigk A; Stingl JC;
Clin Pharmacol Ther; 2013 May; 93(5):402-8. PubMed ID: 23486447
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of antidepressant drugs: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics.
Quaranta S; Dupouey J; Colle R; Verstuyft C
Therapie; 2017 Apr; 72(2):311-318. PubMed ID: 28237405
[TBL] [Abstract][Full Text] [Related]
14. Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge.
Rybakowski JK
CNS Drugs; 2013 Mar; 27(3):165-73. PubMed ID: 23378337
[TBL] [Abstract][Full Text] [Related]
15. Lithium in treatment and prevention of affective disorder. A VA-NIMH collaborative study.
Pokorny AD; Prien RF
Dis Nerv Syst; 1974 Jul; 35(7):327-33. PubMed ID: 17894091
[No Abstract] [Full Text] [Related]
16. The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.
Zivković M; Mihaljević-Peles A; Sagud M; Silić A; Mihanović M
Psychiatr Danub; 2010 Mar; 22(1):112-6. PubMed ID: 20305604
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of combination therapy with lithium and risperidone.
Demling JH; Huang ML; Remmerie B; Mannaert E; Sperling W
Pharmacopsychiatry; 2006 Nov; 39(6):230-1. PubMed ID: 17124646
[No Abstract] [Full Text] [Related]
18. Treatments for late-life bipolar disorder.
Aziz R; Lorberg B; Tampi RR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):347-64. PubMed ID: 17296540
[TBL] [Abstract][Full Text] [Related]
19. Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. Practical issues related to medication selection.
Smoller JW
CNS Spectr; 2006 Mar; 11(3 Suppl 3):5-7. PubMed ID: 17760223
[No Abstract] [Full Text] [Related]
20. Towards the clinical implementation of pharmacogenetics in bipolar disorder.
Salloum NC; McCarthy MJ; Leckband SG; Kelsoe JR
BMC Med; 2014 May; 12():90. PubMed ID: 24885933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
